Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,243 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Pfizer Clear all
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

NCT00458211
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ziprasidone
Drug
Lead sponsor
Bronx Psychiatric Center
Government
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Buffalo, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177
View directory record Official record
Conditions
Celiac Disease, Coeliac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Colorado Springs, Colorado • Hialeah Gardens, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

NCT05489328
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
18
States / cities
Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 2:06 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

NCT01732211
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
PD 0360324, Normal Saline for injection
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

NCT00645034
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
placebo, sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
35 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Laguna Woods, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional

Treatment With SU11248 in Patients With Neuroendocrine Tumors

NCT00056693
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2008 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

NCT00569972
View directory record Official record
Conditions
Insomnia
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

NCT01999972
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
axitinib, crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

NCT00263328
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

NCT00856544
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
46
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Not applicable Interventional

An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002077
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Chicago, Illinois • Newark, New Jersey • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Patient Reported Outcomes (I-PRO) Study for Multidisciplinary Pain Care

NCT02188667
View directory record Official record
Conditions
Chronic Noncancer Pain
Interventions
Providers of Novel Care, Providers of Usual Care
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jul 23, 2026, 2:06 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853
View directory record Official record
Conditions
Healthy Adults
Interventions
Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional

Study Evaluating rhIL-11 in Active Crohn's Disease

NCT00040521
View directory record Official record
Conditions
Crohn Disease, Inflammatory Bowel Disease
Interventions
Recombinant Human Interleukin-11 (rhIL-11)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Arvada, Colorado • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

NCT00723021
View directory record Official record
Conditions
Asthma
Interventions
PF-04191834, zileuton, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • North Dartmouth, Massachusetts • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jul 23, 2026, 2:06 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

NCT00136916
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Jul 23, 2026, 2:06 PM EDT
Completed No phase listed Observational Results available

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

NCT06680206
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Triptans
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 2:06 PM EDT
Recruiting Phase 2Phase 3 Interventional

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

NCT07226999
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
PF-08634404, Atezolizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
44
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 2:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

NCT02349633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PF-06747775, Palbociclib, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 23, 2026, 2:06 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib and Capecitabine for First Line Colon Cancer

NCT00961571
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sunitinib and capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 4 Interventional

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

NCT00418171
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18,239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
San Bernardino, California • ‘Aiea, Hawaii • Schaumburg, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2009 · Synced Jul 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee

NCT00565812
View directory record Official record
Conditions
Osteoarthritis
Interventions
SD-6010, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 99 Years
Enrollment
1,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
120
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Jul 23, 2026, 2:06 PM EDT